EUVIMEDEUVIMED entdecken
Crossref

Omalizumab for severe allergic keratoconjunctivitis: A case series

Marie Mercier, Serge Doan, Imane Elaouane, Zied Chelly, Mélisande Bourgoin-Heck, Nathalie Lambert, Nathalie Cottel, Camille Taillé, Stéphanie Wanin

The Journal of Allergy and Clinical Immunology: In Practice · 2023-11 · 11 (11) · 3528-3530

DOI: 10.1016/j.jaip.2023.07.016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2023-11. Verfasst von Marie Mercier und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Allergology, Armand Trousseau University Hospital, Groupe Hospitalier Universitaire, AP-HP Sorbonne-University, Paris, France. Hauptthemen laut MEDLINE: Anti-Allergic Agents, Hypersensitivity, Keratoconjunctivitis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 9 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Allergic AgentsHypersensitivityKeratoconjunctivitisHumansOmalizumabTreatment Outcome

Substanzen

OmalizumabAnti-Allergic Agents

Autor:innen und Institutionen

  • Department of Pediatric Allergology, Armand Trousseau University Hospital, Groupe Hospitalier Universitaire, AP-HP Sorbonne-University, Paris, France.
  • Department of Ophthalmology, Bichat Hospital, Groupe Hospitalier Universitaire, AP-HP Nord-University de Paris, Paris, France; Department of Ophthalmology, A de Rothschild Foundation Hospital, Paris, France.
  • Department of Ophthalmology, Bichat Hospital, Groupe Hospitalier Universitaire, AP-HP Nord-University de Paris, Paris, France; Department of Ophthalmology, A de Rothschild Foundation Hospital, Paris, France; Department…
  • Department of Respiratory Diseases, Bichat Hospital, Groupe Hospitalier Universitaire, AP-HP Nord-University de Paris, Paris, France.
  • Department of Pediatric Allergology, Armand Trousseau University Hospital, Groupe Hospitalier Universitaire, AP-HP Sorbonne-University, Paris, France. Electronic address: stephanie.wanin@aphp.fr.

Zitieren

APA

Mercier, M., Doan, S., Elaouane, I., Chelly, Z., Bourgoin-Heck, M., Lambert, N., Cottel, N., Taillé, C., & Wanin, S. (2023). Omalizumab for severe allergic keratoconjunctivitis: A case series. The Journal of Allergy and Clinical Immunology: In Practice, 11(11), 3528-3530. https://doi.org/10.1016/j.jaip.2023.07.016

Vancouver

Mercier M, Doan S, Elaouane I, Chelly Z, Bourgoin-Heck M, Lambert N, et al. Omalizumab for severe allergic keratoconjunctivitis: A case series. The Journal of Allergy and Clinical Immunology: In Practice. 2023;11(11):3528-3530. doi:10.1016/j.jaip.2023.07.016

BibTeX
@article{Mercier2023,
  author = {Mercier, Marie and Doan, Serge and Elaouane, Imane and Chelly, Zied and Bourgoin-Heck, Mélisande and Lambert, Nathalie and Cottel, Nathalie and Taillé, Camille and Wanin, Stéphanie},
  title = {Omalizumab for severe allergic keratoconjunctivitis: A case series},
  journal = {The Journal of Allergy and Clinical Immunology: In Practice},
  year = {2023},
  volume = {11},
  number = {11},
  pages = {3528--3530},
  doi = {10.1016/j.jaip.2023.07.016}
}
Kostenlos starten →